Trip.com Group Option Alert: Jun 20 $60 Calls at the Bid: 2000 vs 6112 OI; Earnings 5/19 After Close 

Trip.com Group Option Alert: Jun 20 $60 Calls at the Bid: 2000 @ $4.8 vs 6112 OI; Earnings 5/19 After Close Ref=$61.71

Trip.com Group 株価情報 (NASDAQ: TCOM)

Trip.com Group (NASDAQ:TCOM) 株価情報

TRIP.COM GROUP LTD-ADR

Trip.com Group

Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 79% of sales from accommodation reservations and transportation ticketing in 2024. The rest of revenue comes from package tours and corporate travel. Before the pandemic in 2019, the company generated 25% of revenue from international travel, which is important to its margin expansion. Most of sales come from its domestic platform, but the company is expanding its overseas business. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Tongcheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.

Trip.com Group Limited - American Depositary Shares

Trip.com Group Ltd

News

Watching U.S. Steel Corp; Reuters Cites Person Familiar With The Matter Saying, Trump Will Review CFIUS Recommendations On Nippon Steel Deal; Majority Of CFIUS Member Agencies Believe Any National Security Risks Posed By The Deal Can Likely Be Addressed Through Mitigation; CFIUS Agencies Were Not Unanimous In Their Recommendation To Trump On National Security Implications Of Deal

Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) has outperformed the market over the past 15 years by 10.66% on an annualized basis producing an average annual return of 22.46%. Currently, Regeneron Pharmaceuticals has a market capitalization of $64.44 billion. 
Buying $100 In REGN: If an investor had bought $100 of REGN stock 15 years ago, it would be worth $2,139.25 today based on a price of $596.85 for REGN at the time of writing.
<h3>Regeneron Pharmaceuticals's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747950317_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

REGN

Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years

Soleno Therapeutics, Inc. (Soleno) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNO#NASDAQ">SLNO</a>), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Soleno's Marketing Authorization Application (MAA) seeking regulatory approval of Diazoxide Choline Prolonged-Release Tablets (previously referred to as DCCR) for the treatment of adults and children four years and older with Prader-Willi syndrome (PWS) who have hyperphagia had been validated by the European Medicines Agency (EMA).

Biotech

Global

General

SLNO

Soleno Therapeutics' Marketing Authorization Application For Diazoxide Choline Prolonged-Release Tablets In Treating Hyperphagia In Adults And Children With Prader-Willi Syndrome Validated By European Medicines Agency

One-time Amtagvi Treatment Demonstrated Durable Responses and a Five-year Overall Survival Rate of 20%
Five-year Follow Up is Unprecedented for Any Therapy in Patients with Advanced Melanoma Previously Treated with Immune Checkpoint Inhibitor
SAN CARLOS, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced five-year results from the Phase 2 C-144-01 clinical trial evaluating the individualized T cell therapy Amtagvi&#xAE; (lifileucel).
The C-144-01 trial investigated Amtagvi in patients with advanced melanoma previously treated with anti-PD-1 and targeted therapy, where applicable. The five-year results included meaningful overall survival (OS) results and durable responses following one-time treatment with Amtagvi. These results will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
The long-term data are from 153 patients combined from cohorts 2 and 4 of the C-144-01 trial. With a median follow-up of 57.8 months, patients achieved a median OS of 13.9 months, with 19.7% of patients surviving at the five-year mark. The objective response rate was 31.4%, including complete responses in 5.9% of patients and partial response in 25.5%. Among patients who responded to treatments, the median duration of response was 36.5 months. Nearly a third of responders (31.3%) completed the five-year assessment with ongoing responses.
Adverse events (AEs) were consistent with known safety profiles of nonmyeloablative lymphodepletion and interleukin-2 administration. The incidence of AEs decreased rapidly within the first two weeks after Amtagvi infusion, and there were no new or late-onset treatment-related AEs.

IOVA

Iovance Biotherapeutics Reports 5-Year Phase 2 Data For One-Time Amtagvi Treatment In Advanced Melanoma, Demonstrating Durable Responses, 20% Overall Survival Rate, And Long-Term Safety In Patients Previously Treated With Immune Checkpoint Inhibitors, To Be Presented At ASCO 2025

- Sanofi today announces the formal opening of the company's new flagship US offices, unveiling a state-of-the-art modern workplace fostering collaboration and innovation with the ultimate goal of bringing medicines and vaccines to patients faster.

Sanofi Opens New $130M Offices In Morristown, NJ

Silvercorp Metals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SVM#AMEX">SVM</a>) reported quarterly earnings of $0.07 per share which missed the analyst consensus estimate of $0.08 by 12.5 percent. This is a 250 percent increase over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $75.11 million which missed the analyst consensus estimate of $75.84 million by 0.96 percent. This is a 75.99 percent increase over sales of $42.68 million the same period last year.

Earnings

Earnings Misses

Silvercorp Metals Q4 Adj. EPS $0.07 Misses $0.08 Estimate, Sales $75.11M Miss $75.84M Estimate

PDSB

PDS Biotechnology Reports  Extended Follow-Up Results from VERSATILE-002 And Upcoming Versamune HPV Trial Data to Be Presented at ASCO 2025

-&nbsp; 63% response rate observed among 43 evaluable patients
-&nbsp; 79% overall survival rate at 12-months; 9 months median progression-free survival
-&nbsp; Conference Call on Thursday, May 22 at 5:30 p.m. ET &nbsp;
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=9FhYyVwI9DsnInrbxOt--inJgjOKfmMbph8kfn71rg_QOcr1YnuZK2hzrUydrWlBOD1YgWDc-HEZ2Du9ltkH1g==">Merus N.V.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics&#xAE;, Triclonics&#xAE; and ADClonics&#xAE;), today announced interim clinical data as of a February 27, 2025 data cutoff from the ongoing phase 2 trial of the bispecific antibody petosemtamab in combination with pembrolizumab. These data will be presented by Dr. Carla M. L. van Herpen M.D. Ph.D., Radboud University Medical Center, Nijmegen, Netherlands at the 2025 American Society of Clinical Oncology&#xAE; (ASCO&#xAE;) Annual Meeting on Monday, June 2 at 9 a.m. - 12:00 p.m. CT.

MRUS

Merus Reports Interim Phase 2 Data Showing 63% Response Rate And 79% 12-Month Overall Survival For Petosemtamab Plus Pembrolizumab In Ongoing Trial, To Be Presented At ASCO 2025 With Conference Call Scheduled For May 22

<ul>
<li>Final data from the&nbsp;GAVRETO&#xAE; (pralsetinib) Phase 1/2 ARROW study in RET fusion-positive NSCLC and other solid tumors &nbsp;</li>
<li>Supportive data for&nbsp;REZLIDHIA&#xAE; (olutasidenib) utilization in patients with mIDH1 R/R AML</li>
</ul>
SOUTH SAN FRANCISCO, Calif., May 22, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>), a commercial stage biotechnology company focused on hematologic disorders and cancer,&nbsp;today announced seven upcoming poster presentations at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) 2025 Congress. The ASCO Annual Meeting is being held in Chicago, Illinois and virtually from May 30 to June 3, 2025. The EHA2025 Congress is being held in Milan, Italy and virtually from June 12 to June 15, 2025.

RIGL

Rigel Pharmaceuticals To Present Final GAVRETO Phase 1/2 ARROW Study Data In RET Fusion-Positive NSCLC And Solid Tumors, Along With Supportive REZLIDHIA Data For mIDH1 R/R AML At ASCO And EHA 2025 Conferences

<a href="https://www.globenewswire.com/Tracker?data=bHn1Hf19BGqrGwRLALx_k_fPUFbYFcEgM0wkZMsN8XYSuALVVBXIEXwwXZ9C0yDTGi5_Aq10ZSnJsj1bDIxqZw==">IMUNON</a>, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it has filed a request for withdrawal with the Securities and Exchange Commission (SEC) of the Company's Registration Statement on Form S-1 (No. 333-286403), as amended, originally filed on April 4, 2025 (Registration Statement), as the Company no longer intends to pursue a public offering under the Registration Statement at this time. The Registration Statement has not been declared effective by the SEC, and no securities have been sold in connection with the offering described in the Registration Statement.

Offerings

IMNN

IMUNON Announces Withdrawal Of Form S-1 Registration Statement; No Securities Have Been Sold In Connection With The Offering Described In The Registration Statement

– Zanzalintinib in combination with nivolumab demonstrated an objective response rate of 63% and a disease control rate of 90% –
– Additional results from dose-finding cohorts will also be presented –
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.exelixis.com%2F&amp;esheet=54259233&amp;newsitemid=20250522412302&amp;lan=en-US&amp;anchor=Exelixis%2C+Inc.&amp;index=1&amp;md5=6eda2c7d890705b396b87b517f683533">Exelixis, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) today announced results from an expansion cohort of the phase 1b/2 STELLAR-002 trial evaluating zanzalintinib in combination with either nivolumab (Opdivo&#xAE;) or a fixed-dose combination of nivolumab and relatlimab (Opdualag&#x2122;) in patients with previously untreated advanced clear cell renal cell carcinoma (RCC). These findings, as well as data from multiple dose-escalation cohorts from STELLAR-002, will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

EXEL

Exelixis To Present STELLAR-002 Trial Data At ASCO 2025 Showing Zanzalintinib Plus Nivolumab Achieved 63% Response Rate And 90% Disease Control In Untreated Advanced Clear Cell RCC, Alongside Additional Dose-Finding Results

KURA

Kura Oncology And Kyowa Kirin Reveal Monotherapy Data for Ziftomenib In Oral Presentation At The 2025 ASCO Annual Meeting

<a href="https://www.globenewswire.com/Tracker?data=fqSEEKcCS3WL0DkIPg-ZGq8dUPYHc2FrRehCH0411kcdEWWGPvAiXSaBcKcBcUF0KTdZf4c-AzwvEEY-66QCw2DrMjRyz95mHIC7kZce8lmixxDUGiJw9b38560NwUoN">Cullinan Therapeutics, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEM#NASDAQ">CGEM</a>), Taiho Pharmaceutical Co., Ltd., and Taiho Oncology, Inc. today announced new positive results from the pivotal Phase 2b cohorts of the <a href="https://www.globenewswire.com/Tracker?data=dgN-apaMAiMXorFEZyxCmM3xuc2Ghed0t69_SRcbPmIPMy4FuqNOSt9X3ASGA91zWsyP-sjWjqs_cfsARTCEysjsqJMoXEMt0wMz2vx9SxwAK6VYvU_dp6GlHieDYKqR">REZILIENT1 trial</a>, a Phase 1/2 clinical trial of zipalertinib monotherapy in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (ex20ins) who have received prior therapy. These data will be presented on Sunday, June 1 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting as an oral presentation during the "Lung Cancer&nbsp;–&nbsp;Non-Small Cell Metastatic" session from 9:00 AM-9:12 AM CDT (Abstract #8503).

CGEM

Cullinan Therapeutics And Taiho To Present Phase 2b Results From REZILIENT1 Trial Of Zipalertinib In Previously Treated EGFR ex20ins NSCLC At ASCO 2025

Studies include nearly 25,000 patients across multiple indications, showcasing the clinical impact of Signatera
<ul>
<li>Breast: 8 accepted abstracts (4 oral presentations), including interim analysis from the randomized Signatera-guided interventional DARE trial; a large real-world study of metastatic treatment monitoring; and two readouts from the ISPY-2 trial</li>
<li>Signatera Genome: Large-scale, pan-cancer performance of Signatera Genome assay</li>
<li>GI, GU, Skin, Sarcoma: Significance of Signatera MRD and dynamics to predict recurrence, progression, and treatment response across multiple disease subtypes&nbsp;</li>
</ul>
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54259385&amp;newsitemid=20250522046212&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=1&amp;md5=5e339fe2f98c1d509dc06e311667dc9b">Natera, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), a global leader in cell-free DNA and precision medicine, today announced that data from more than 25 Signatera studies will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30 - June 3, 2025 in Chicago, IL.
Together with its collaborators, Natera will showcase the clinical utility of Signatera across 10 different cancer types. This extraordinary breadth of data includes analyses of thousands of patients, demonstrating Natera's leadership in circulating tumor DNA (ctDNA) monitoring and molecular residual disease (MRD) assessment.

NTRA

Natera To Present Data From 25 Signatera Studies Covering Nearly 25,000 Patients Across 10 Cancer Types At ASCO 2025, Highlighting MRD Detection, Treatment Monitoring, And Pan-Cancer Utility Including Breast, GI, GU, Skin, And Sarcoma Trials

<ul>
<li>Plenary session to highlight use of Guardant360 CDx test in detecting emerging ESR1 mutations during first line endocrine therapy in advanced breast cancer in Phase 3 SERENA-6 trial</li>
<li>Oral session to feature largest study evaluating tissue-free epigenomic-based molecular residual disease (MRD) detection in colon cancer using Guardant Reveal</li>
</ul>
Guardant Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>), a leading precision oncology company, today announced the company and its research collaborators will present data from more than 19 studies, including a landmark plenary session on the Phase 3 SERENA-6 trial, demonstrating the critical role of Guardant liquid biopsy tests in cancer screening, therapy selection and recurrence monitoring at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago.
Featured presentations demonstrate the use of Guardant's portfolio of blood tests, real-world data and AI to identify genomic and epigenomic biomarkers that can inform treatment decisions across a variety of solid tumor types. Studies also highlight new capabilities of the Guardant360 Liquid test to identify molecular tumor type in carcinomas of unknown primary and confirm the absence of actionable biomarkers, both enabled by the Guardant Infinity&#x2122; smart liquid biopsy platform, Presentation highlights include:
<ul>
<li>Abstract LBA4 plenary session demonstrating the use of the Guardant360&#xAE; CDx test in detecting emergent ESR1 mutations during first-line endocrine-based therapy and ahead of disease progression in patients with HR+/HER2- advanced breast cancer in the Phase 3 SERENA-6 trial</li>
<li>Abstract 3504 oral session evaluating tissue-free epigenomic-based molecular residual disease (MRD) detection using Guardant Reveal&#x2122; in stage III colon cancer patients after surgery and prior to adjuvant therapy. This study showed a robust prognostic utility of Reveal to identify patients with poorer disease-free and overall survival in a large clinical trial cohort of over 2,000 patients with a median follow-up of 6.1 years.</li>
<li>Abstract 3584 providing analytic and clinical validation of an algorithm to predict the absence of actionable mutations in ctDNA-negative colorectal and non-small cell lung cancer samples, utilizing genomic and epigenomic profiling with the Guardant360 Liquid test.</li>
<li>Abstract 3073 demonstrating application of an epigenomic-based classifier to identify tumor type on liquid biopsy in cancer of unknown primary origin. Study provides validation data for the new molecular tumor type feature of Guardant360 Liquid utilizing DNA methylation signatures across thousands of cancer-specific differentially methylated regions for 14 cancer types.</li>
</ul>

Guardant Health To Showcase Breakthrough Data At ASCO 2025 Including Plenary Results From Phase 3 SERENA-6 Using Guardant360 CDx To Detect ESR1 Mutations In Advanced Breast Cancer And Study Of Over 2,000 Patients Highlighting Epigenomic MRD Detection In Colon Cancer With Guardant Reveal

LEGN

Legend Biotech Reveals New Oncologic & Hematologic Therapeutic Developments At ASCO, EHA, And ASGCT

<ul>
<li>First presentation of results from Phase 1/2 clinical trial of investigational rinatabart sesutecan (Rina-S&#xAE;) in patients with recurrent/advanced endometrial cancer</li>
<li>Presentation of long-term follow-up data from analysis of Phase 1/2 EPCORE&#x2122; NHL-1 study of epcoritamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)</li>
</ul>
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.genmab.com&amp;esheet=54259160&amp;newsitemid=20250522461621&amp;lan=en-US&amp;anchor=Genmab+A%2FS&amp;index=1&amp;md5=8f6ec8943aeee8a465b09be90447b768">Genmab A/S</a> (NASDAQ:<a href="https://www.benzinga.com/stock/GMAB#NASDAQ">GMAB</a>) announced today that it will present new research from its comprehensive development program evaluating its late-stage portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30 to June 3 in Chicago, Illinois.
The presentations will include the first disclosure of results from a Phase 1/2 trial evaluating rinatabart sesutecan (Rina-S&#xAE;), an investigational folate receptor-alpha (FRa)-targeted, TOPO1-inhibor antibody-drug conjugate (ADC), in patients with recurrent/advanced endometrial cancer. Additionally, results from an analysis of the Phase 1/2 EPCORE NHL-1 study of epcoritamab, a T-cell–engaging bispecific antibody administered subcutaneously, including long-term follow-up in adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who remain in complete response (CR) at 2 years, will be presented.

GMAB

Genmab To Present First Clinical Results For Rina-S In Advanced Endometrial Cancer And Long-Term Follow-Up Data For Epcoritamab In R/R DLBCL At ASCO 2025, Highlighting Progress In Late-Stage Oncology Pipeline

Antero Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AR#NYSE">AR</a>) has outperformed the market over the past 5 years by 47.35% on an annualized basis producing an average annual return of 61.63%. Currently, Antero Resources has a market capitalization of $12.14 billion. 
Buying $100 In AR: If an investor had bought $100 of AR stock 5 years ago, it would be worth $1,103.11 today based on a price of $39.05 for AR at the time of writing.
<h3>Antero Resources's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747949424_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Antero Resources 5 Years Ago Would Be Worth This Much Today

<ul>
<li>Phase 2 (Actuate-1801 Part 3B) trial topline results meet primary endpoint of improved survival in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)</li>
<li>Oral presentation at the American Society of Clinical Oncology (ASCO) annual meeting to highlight statistically significant improvement in median overall survival and 1-year survival rate in patients treated with the combination of elraglusib and gemcitabine/nab-paclitaxel (GnP) compared to GnP alone</li>
<li>Company to host KOL event on May 31, 2025, to review data presented &nbsp;</li>
</ul>
CHICAGO and FORT WORTH, Texas, May 22, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACTU#NASDAQ">ACTU</a>) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced the online publication of the abstract accepted as an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, to take place May 30-June 3, in Chicago, Illinois.
The oral presentation will highlight topline Phase 2 (Actuate-1801 Part 3B) data of elraglusib in combination with GnP in first-line mPDAC and will be presented by Devalingam Mahalingam, MD, PhD, of Northwestern University Feinberg School of Medicine. The topline data demonstrate clinically meaningful and consistent improvements across primary efficacy measures compared to treatment with GnP alone and reinforce the potential of elraglusib to address key unmet needs in this patient population.
The published abstract describes <a href="https://www.globenewswire.com/Tracker?data=rvCxRQJ86pwY2CoXwaeU2g2D3g9pDg9QNbKR-bVrxu3oRKWKzAiIb8QYrKX1c1OQ-l-f0biLeWNHaaoZetPU8aEC_78cv1d_s7y4Tr71DwQA6_Cedb0xSG4HoqpjUmOxWdz-mSEPil0u_S0N7iwA8dAtpxKxBfU9SNn3VSlNA3HeojBERvf6aqfJifeeYI2CcrAjjdplkccoMW_2mZy4MHs589iwSbi1sIKadmNXaY6zx1P5eRbnN7hvTFZmFSaBv17KsPaRe2FBLXf7pEuzmHO7KUjC-sHZcWB8b3kK8hc=">preliminary results</a> reported in December 2024, demonstrating that treatment with elraglusib in combination with GnP resulted in statistically significant increases in 1-year survival rate and median overall survival versus treatment with GnP alone. The combination treatment also resulted in increased Objective Response Rates (ORR) and Disease Control Rates (DCR) in the elraglusib/GnP combination arm versus the GnP control arm.

ACTU

Actuate Therapeutics Announces Phase 2 Trial Success As Elraglusib Combo Shows Statistically Significant Survival Benefit In First-Line mPDAC, To Be Featured In ASCO 2025 Oral Presentation And Reviewed At May 31 KOL Event

Completed assessment of more than 2,800 patients highlights the profound impact of the test in helping to predict the likelihood of extended endocrine therapy benefit for patients with HR+ breast cancer to support more informed care decisions
Hologic, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) and its subsidiary, Biotheranostics, Inc., today announced new data demonstrating the significant clinical impact of the Breast Cancer Index&#xAE; (BCI&#xAE;) test, which will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting on June 2, 2025.

HOLX

Hologic And Biotheranostics To Present New Data At ASCO 2025 Highlighting Breast Cancer Index Test's Impact In Guiding Extended Endocrine Therapy Decisions For Over 2,800 HR+ Breast Cancer Patients

Press Releases

Trip.com Group Limited Reports Unaudited Third Quarter of 2024 Financial Results

Trip.com Group Announces Changes in Board Composition

Trip.com Group Limited to Report Fourth Quarter and Full Year of 2024 Financial Results on February 24, 2025 U.S. Time

Trip.com Group Limited Reports Unaudited Fourth Quarter and Full Year of 2024 Financial Results

Baidu Announces Proposed Offering of Exchangeable Bonds

Baidu Announces Pricing of US$2 Billion Offering of Zero Coupon Exchangeable Bonds

Trip.com Group Filed 2024 Annual Report on Form 20-F

Trip.com Group Limited to Report First Quarter of 2025 Financial Results on May 19, 2025 U.S. Time

Trip.com Group Limited Reports Unaudited First Quarter of 2025 Financial Results

Trip.com Group to Hold Annual General Meeting on June 30, 2025

BIDU

TCOM

Airbnb

Atour Lifestyle Holdings Limited - American Depositary Shares

Atour Lifestyle Holdings

Booking Holdings

Choice Hotels International, Inc. Common Stock

Choice Hotels Intl

Expedia Group

Global Business Travel Group, Inc. Class A Common Stock

Global Business Travel

GreenTree Hospitality Group Ltd. American depositary shares, each representing one Class A ordinary share

GreenTree Hospitality Gr

Hyatt Hotels Corporation Class A Common Stock

Hyatt Hotels

Hilton Grand Vacations

Hilton Worldwide Holdings Inc. Common Stock

Hilton Worldwide Holdings

H World Group Limited - American Depositary Shares

H World Group

Intercontinental Hotels Group American Depositary Shares (Each representing one Ordinary Share)

Comments

Trip.com Group

Unusual Options Activity for

ニュース

パートナーシップ

ベンジンガ・グローバル